This systematic review identified published studies that evaluated the use of pro re nata (PRN) medication in patients with acute agitation or aggression of undifferentiated etiology.
Methods
A literature search was conducted of PubMed and MEDLINE for randomized controlled trials (RCTs) that evaluated the use of PRN medications for individuals with undifferentiated agitation or aggression. Bibliographic databases of published articles were also searched for additional studies.
Results
A total of 15 studies were identified that assessed the effects of first-generation antipsychotics (FGAs), second-generation antipsychotics (SGAs), benzodiazepines, and combination therapies. All RCTs showed variable degrees of sedation and decreased agitation over time with the use of these medications, as well as variable levels of adverse events.
Conclusions
Evidence exists to support the use of specific SGAs as first-line PRN medications in the management of acutely agitated individuals. While evidence exists to support the use of FGAs, benzodiazepines, and combination therapy, efficacy is similar for each class, and SGAs appear to have the most favorable adverse effect profile.
Get full access to this article
View all access options for this article.
References
1.
Martínez-RagaJAmoreMDi SciascioG, . 1st International Experts’ Meeting on Agitation: Conclusions regarding the current and ideal management paradigm of agitation. Front Psychiatry.2018; 9: 54.
2.
GarrigaMPacchiarottiIKasperS. Assessment and management of agitation in psychiatry: Expert consensus. World J Biol Psychiatry. 2016; 17: 86-128.
3.
GilliesDSampsonSBeckA. Benzodiazepines for psychosis-induced aggression or agitation. Cochrane Database Syst Rev.2013; 4: CD003079. doi:org.10.1002/14651858.
4.
National Collaborating Centre for Mental Health (UK). Violence and aggression: short-term management in mental health, health and community settings: updated edition. London: British Psychological Society. 2015. (NICE Guideline, No. 10.).
5.
GoedhardLEStolkerJJHeerdinkER. Pharmacotherapy for the treatment of aggressive behavior in general adult psychiatry: a systematic review. J Clin Psychiatry.2006; 67: 1013-1024.
6.
GlassOMForesterBPHermidaA P. Electroconvulsive therapy (ECT) for treating agitation in dementia (major neurocognitive disorder) - a promising option. Int Psychogeriatrics.2017; 29: 717-726.
7.
LeuchtSCorvesCArbterD. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet.2009; 373: 31-41.
8.
DavisJMChenN.Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol.2004; 24: 192-208.
9.
ZhuBAscher-SvanumHFariesDE. Cost of antipsychotic polypharmacy in the treatment of schizophrenia. BMC Psychiatry.2008; 8: 19.
AlexanderJTharyanPAdamsC. Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting. pragmatic randomised trial of intramuscular lorazepam v. haloperidol plus promethrazine. Br J Psychiatry.2004; 185: 63-69.
13.
BaldacaraLSanchesMCordeiroDC. Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone. Rev Bras Psiquiatr.2011; 33: 30-39.
14.
BieniekSOwnbyRPenalverA. A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy.1998; 18: 57-62.
15.
CalverLDrinkwaterVGuptaR. Droperidol v. haloperidol for sedation of aggressive behaviour in acute mental health: randomised controlled trial. Br J Psychiatry.2015; 206: 223-228.
16.
HufGCoutinhoESFAdamsCE. Rapid tranquillisation in psychiatric emergency settings in Brazil: pragmatic randomised controlled trial of intramuscular haloperidol versus intramuscular haloperidol plus promethazine. BMJ.2007; 335: 869.
17.
IsbisterGKCalverLAPageCB. Randomized controlled trial of intramuscular droperidol versus midazolam for violence and acute behavioral disturbance: the DORM study. Ann Emerg Med.2010; 56: 392-401.
18.
IsenbergDLJacobsD.Prehospital Agitation and Sedation Trial (PhAST): a randomized control trial of intramuscular haloperidol versus intramuscular midazolam for the sedation of the agitated or violent patient in the prehospital environment. Prehosp Disaster Med.2015; 30: 491-495.
19.
MantovaniCLabateCMSponholzAJ. Are low doses of antipsychotics effective in the management of psychomotor agitation? A randomized, rated-blind trial of 4 intramuscular interventions. J Clin Psychopharmacol.2013; 33: 306-312.
20.
MartelMSterzingerAMinerJ. Management of acute undifferentiated agitation in the emergency department: a randomized double-blind trial of droperidol, ziprasidone, and midazolam. Acad Emerg Med.2005; 12: 1167-1172.
21.
NobayFSimonBCLevittMA. A prospective, double-blind, randomized trial of midazolam versus haloperidol versus lorazepam in the chemical restraint of violent and severely agitated patients. Acad Emerg Med.2004; 11: 744-749.
22.
PrattsMCitromeLGrantW. A single-dose, randomized, double-blind, placebo-controlled trial of sublingual asenapine for acute agitation. Acta Psychiatr Scand.2014; 130: 61-68.
23.
RaveendranNSTharyanPAlexanderJ. Rapid tranquillisation in psychiatric emergency settings in India: pragmatic randomised controlled trial of intramuscular olanzapine versus intramuscular haloperidol plus promethazine. BMJ.2007; 335: 865.
24.
ResnickMBurtonBT. Droperidol vs. haloperidol in the initial management of acutely agitated patients. J Clin Psychiatry.1984; 45: 298-299.
25.
ThomasHJSchwartzEPetrilliR.Droperidol versus haloperidol for chemical restraint of agitated and combative patients. Ann Emerg Med.1992; 21: 407-413.
26.
TREC Collaboration Group.Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ.2003; 327: 708-713.
BattagliaJMossSRushJ. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med.1997; 15: 335-340.
32.
VilkeGMWilsonMP. Agitation: what every emergency physician should know. Emerg Med Rep.2009; 30: 233-244.
33.
AllenMHCurrierGWCarpenterD. The expert consensus guideline series. Treatment of behavioral emergencies 2005. J Psychiatr Pract.2005; 11: 5-108.
34.
WilsonMPPepperDCurrierGW. The psychopharmacology of agitation: consensus statement of the american association for emergency psychiatry project BETA psychopharmacology workgroup. W J Emerg Med.2012; 13: 26-34.
35.
Droperidol [package insert]. Shirley, NY: American Regent, Inc.; 2013.
